Targeted Therapies in Sarcomas: Challenging the Challenge by Martín Liberal, Juan et al.
Hindawi Publishing Corporation
Sarcoma
Volume 2012, Article ID 626094, 13 pages
doi:10.1155/2012/626094
Review Article
Targeted TherapiesinSarcomas:ChallengingtheChallenge
Juan Mart´ ın Liberal,1 Laura Lagares-Tena,1 Miguel S´ ainz-Jaspeado,1 Silvia Mateo-Lozano,2
Xavier Garc´ ıadel Muro,1 andOscar M.Tirado1
1Laboratori d’Oncolog´ ıa Molecular, Institut d’Investigaci´ o Biom` edica de Bellvitge (IDIBELL),
L’Hospitalet de Llobregat, 08908 Barcelona, Spain
2Nanomedicine Research Program, Molecular Biology and Biochemistry Research Center, CIBBIM-Nanomedicine,
Vall d’Hebron Hospital Research Institute, 08035 Barcelona, Spain
Correspondence should be addressed to Oscar M. Tirado, omartinez@idibell.cat
Received 7 March 2012; Accepted 27 March 2012
Academic Editor: Peter Choong
Copyright © 2012 Juan Mart´ ın Liberal et al. This is an open access article distributed under the Creative Commons Attribution
License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly
cited.
Sarcomas are a heterogeneous group of mesenchymal malignancies that very often lead to death. Nowadays, chemotherapy is the
only available treatment for most sarcomas but there are few active drugs and clinical results still remain very poor. Thus, there
is an imperious need to ﬁnd new therapeutic alternatives in order to improve sarcoma patient’s outcome. During the last years,
there have been described a number of new molecular pathways that have allowed us to know more about cancer biology and
tumorigenesis. Sarcomas are one of the tumors in which more advances have been made. Identiﬁcation of speciﬁc chromosomal
translocations, some important pathways characterization such as mTOR pathway or the insulin-like growth factor pathway,
the stunning development in angiogenesis knowledge, and brand new agents like viruses have lead to the development of new
therapeutic options with promising results. This paper makes an exhaustive review of preclinical and clinical evidence of the most
recent targeted therapies in sarcomas and provides a future view of treatments that may lead to improve prognosis of patients
aﬀected with this disease.
1.Introduction
Sarcomas are a rare and heterogeneous group of malignant
tumors of mesenchymal origin. They can occur through
all the lifespan and aﬀect patients of all ages, although
certain speciﬁc subtypes are more frequent in children
and young adults. Almost every part of the body may be
involved, bone and soft-tissue being the most typical place
of arising. Sarcomas are associated with bad prognosis and
approximately 50% of all patients develop metastases even
if they are diagnosed at early stages. Lungs are the most
frequent site of dissemination and metastases are the ﬁnal
cause of death in almost all these patients [1]. These high
mortality levels make sarcomas one of the most challenging
tumors in oncology.
For most sarcomas, chemotherapy is currently the only
available treatment. Unfortunately, a very limited number of
usefuldrugsareactiveagainstthisdiseaseandresponsesused
to be poor and short. In fact, advanced-stage patients treated
with the most active drugs in this disease (anthracyclines
and ifosfamide) achieve only a median survival of around
1y e a r[ 2]. Thus, it is necessary to identify new agents to
improve therapy for patients aﬀected by this often mortal
condition.
In the last years, great advances have been made in the
understanding of sarcomas’ molecular biology [3]. Conse-
quently, new targeted compounds have been developed and
tested in order to improve eﬃcacy and outcome achieved
with classic drugs. This paper will extensively review the
most relevant pathways in soft tissue and bone sarcomas and
the preclinical and clinical experience with the most recent
targeted therapies.
2. Angiogenesis
In the last years, angiogenesis has been one of the most
studied processes in tumor biology with interesting results.
Patients with several malignancies such as renal cancer or2 Sarcoma
colorectal cancer are currently being treated with angio-
genic inhibitors alone or in combination with conventional
chemotherapy. These patients achieve signiﬁcant improve-
ment in overall survival (OS) and/or progression-free sur-
vival (PFS) [4]. Sarcomas have been recently added to the
group of tumors in which angiogenesis is known to play an
important role.
One of the key eﬀectors in angiogenesis is the vascular
endothelial growth factor (VEGF). It is well known that
the interaction between VEGF and its receptor 2 (VEGF-
R2) is the most crucial step in angiogenesis [5–7]a n d
there are some studies that relate VEGF with sarcomas. A
study by Potti et al. published in 2004 correlated VEGF
serum levels with outcome in patients with sarcoma [8]. 68
out of 273 patients (24.9%) included in the study showed
VEGFoverexpression.Themostcommonsarcomasinwhich
VEGF overexpression was detected were malignant ﬁbrous
histiocytoma (30%), carcinosarcoma (30%), leiomyosar-
coma (25%), and dermatoﬁbrosarcoma (20%) but VEGF
overexpression had prognostic value only in patients aﬀected
with leiomyosarcoma. In addition, this was associated with a
shorter survival. Graeven et al. also determined VEGF serum
levels in 85 patients with STS before surgery. They found
a very strong correlation between tumor grade and VEGF
serum levels, the poorest diﬀerentiated tumors being the
ones with the highest VEGF levels [9]. Another study was
designed to assess the correlation between VEGF and tumor
grade [10]. Results conﬁrmed that tumor grade correlated
with VEGF expression. Furthermore, 78% of patients who
died of sarcoma progression had high VEGF levels. However,
VEGF expression was not found to be an independent
predictor of OS or disease-free survival (DFS). In contrast, a
studybyIyodaetal.thatcorrelatedVEGFoverexpressionand
survival in patients with soft-tissue sarcomas (STSs) of the
thorax found this correlation statistically signiﬁcant. Thus,
patients with absent or faint VEGF expression had higher
5-year DFS than patients with a strong VEGF expression
(83.3% versus 13.2%, resp.) [11].
Hypoxia-inducible factor1α (HIF-1α) is another impor-
tant player in angiogenesis since it is a transcription factor
that acts as an upstream regulator of VEGF. In a 2006 paper
by Shintani et al. HIF-1α expression was determined by
immunohistochemistry in a group of 49 specimens of STS.
The analysis showed that patients with a strong or moderate
expression of HIF-1α had poorer OS than those with a weak
or negative expression [12].
There are many other angiogenesis markers but not all
of them are so clearly related with prognosis and survival
as VEGF and HIF-1α in sarcomas. Microvascular density
(MVD) is one of them. Thus, in a work by Comandone et al.,
patientswithhighMVDhadworseOSandDFSthanpatients
with lower MVD [13]. In contrast, 3 other authors reported
results that did not conﬁrm this correlation between MVD
and prognosis, so the real role of MVD in sarcomas remains
unclear [14–16].
2.1. Angiogenic Inhibitors. These previous data provided a
rationale for the development of preclinical and clinical
studieswithangiogenicinhibitorsinsarcomas.Anincreasing
number of these drugs have been developed in the last years
andtheeﬀectsofmanyofthemhavebeenassessed(Figure 1).
2.1.1. Small-Molecule VEGF-R Inhibitors. Sunitinib is a
multitargeted tyrosine kinase inhibitor (TKI) active against
VEGF-R1, 2, 3, PDGFR and KIT, among others. In 2009,
Stacchiotti et al. reported 3 responses and 1 stabilization
in a cohort of 5 patients aﬀected with advanced alveolar
STS treated with sunitinib [17] .T h es a m ey e a r ,ap h a s eI I
trial of sunitinib in the treatment of non-GIST sarcomas
was published. A cohort of 53 patients with advanced non-
GIST STS received 37.5mg of sunitinib daily. 10 of these
patients (20%) achieved stable disease (SD) for at least 16
weeks and, interestingly, 1 patient aﬀected with desmoplastic
round cell tumor (DSRCT) achieved a durable partial
response (PR) for 56 weeks [18]. Focusing on 3 speciﬁc
histologies (leiomyosarcoma, liposarcoma, and malignant
ﬁbrous histiocytoma), a phase II study was reported in 2010.
In this trial, 48 patients with unresectable or metastatic STS
of the histologies mentioned previously were treated daily
with50mgofsunitinibmalatefor4weeksevery6weeks.3or
less prior lines of therapy were allowed. Median PFS and OS
for liposarcoma, leiomyosarcoma, and ﬁbrous histiocytoma
were 3.9 and 18.6, 4.2 and 10.1, and 2.5 and 13.6 months,
respectively. The 3-month progression-free rates (PFRs) in
the untreated and pretreated patients with liposarcoma,
leiomyosarcoma, and ﬁbrous histiocytoma were 75% and
69.2%, 60%, and 62.5%, and 25% and 44.4%, respectively.
The authors concluded that the 3-month PFR of >40%
suggests activity for sunitinib at least in liposarcomas and
leiomyosarcomas [19]. In contrast to these studies, the
Gynecologic Oncology Group conducted a phase II study to
assess the eﬃcacy of sunitinib in the treatment of recurrent
or persistent uterine leiomyosarcoma with disappointing
results: of 25 patients enrolled, just 2 achieved a PR and the
median PFS was 1.5 months [20].
Sorafenib is another TKI recently added to the group of
drugs with activity in sarcomas. This TKI targets VEGF-R 2
and 3, PDGFR, Raf, and KIT, and several preclinical studies
have demonstrated eﬃcacy in diﬀerent soft-tissue and bone
sarcoma cell lines [20–25]. These encouraging preclinical
results, together with some case reports of responses in
patients with sarcomas treated with sorafenib [26, 27], led
to the development of several clinical trials. In 2009, Maki
et al. published a phase II trial of sorafenib in patients with
metastatic or recurrent sarcomas [28]. A total of 145 patients
with diﬀerent types of sarcomas were enrolled but just the
angiosarcoma patients met the response rate (RR) primary
end point planned for the study (5 out of 37 patients, 14%).
Another study pointed out osteosarcoma as other sarcoma
subtype in which sorafenib showed activity. The Italian
group conducted a phase II trial of sorafenib in relapsed
and unresectable high-grade osteosarcoma after failure of
standard therapy that showed 3 PRs (8%), 2 minor responses
(6%), and 12 SDs (34%). Furthermore, median PFS and OS
were 4 and 7 months, respectively, demonstrating sorafenib
as the ﬁrst targeted therapy active in osteosarcoma [29]. In
order to ﬁnd other responsive histologies to sorafenib, the
Southwest Oncology Group (SWOG) promoted a phase IISarcoma 3
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Figure 1: Inhibition of angiogenesis by blocking diﬀerent tumorigenic signaling pathways.
trial testing its activity in advanced vascular sarcoma, high-
grade liposarcoma, and leiomyosarcoma [30]. No responses
were found and just 6 out of 8 patients with vascular
sarcoma achieved clinical beneﬁt. New strategies, such as
discontinuationtreatment,havealsobeentested.Thus,Pacey
et al. assessed the eﬃcacy of sorafenib in STS in a phase II
randomized discontinuation trial [31]. Evidence of activity
was found, since some tumor regressions were observed
including 1 objective partial response.
Pazopanib is a new TKI that also has eﬀects on angio-
genesis by blocking VEGF-R 1, 2, and 3, PDGFR, and KIT.
A phase II trial performed by the European Organisation for
Research and Treatment of Cancer (EORTC) in patients with
relapsed or refractory advanced STS treated with pazopanib
achieved promising results [32]. 142 patients were enrolled
andtheywereclassiﬁedin4diﬀerentgroups:adipocytic STS,
leiomyosarcomas, synovial sarcomas, and other STS types.
Pazopanib in adipocytic STS patients showed insuﬃcient
activity but PFR at 12 weeks in the remaining groups was
encouraging: 18 (44%) of 41 patients in the leiomyosarcoma
cohort, 18 (49%) of 37 in the synovial sarcomas, and 16
(39%) of 41 in the other STS types. These data led to
the ﬁrst placebo-controlled randomized phase III trial to
date with a VEGFR inhibitor (pazopanib) in advanced STS.
The results, reported in the 2011 ASCO Annual Meeting,
achieved a signiﬁcant increase in PFS showing the relevance
ofangiogenesisinsarcomas[33].Finally,theactivityofanew
TKI named dasatinib has been assessed in several sarcoma
cell lines. This drug blocks VEGF-R2 and PDGFR and has
the unique property of inhibiting the Src family. This latter
eﬀect leads to the inhibition of migration and invasion in
diﬀerent sarcoma cell lines in vitro, which can lead to further
development of clinical trials [34–37].
2.1.2. Anti-VEGF Antibodies. Bevacizumab is the only mon-
oclonal anti-VEGF antibody to date that has been proved
to have activity in sarcomas. A set of preclinical studies
demonstrated activity in sarcoma models in vitro and in
vivo [38–42]. The experience achieved in a number of other
malignancies such as colon, breast, or non-small-cell lung
cancer, has shown that the eﬀect of bevacizumab in combi-
nation with chemotherapy is higher than as a single agent.
This strategy was ﬁrst assessed in sarcomas by D’Adamo el
al. in a phase II trial of doxorubicin and bevacizumab in
patients with metastatic STS [43]. There were just 2 partial
responses but 11 of 17 patients recruited (65%) achieved
stable disease for 4 cycles or more. Interestingly, cardiac
toxicity was signiﬁcantly high and 4 patients developed
cardiac toxicity grade 2, 1 patient grade 3, and 1 patient
grade 4 despite prophylactic treatment with dexrazoxane.
These results suggest the activity of this combination in
sarcomas but make necessary ﬁnding safer schedules. The
eﬃcacy of bevacizumab in combination with other drugs
has also been explored in a recently published phase IB
trial. In this study, 38 chemotherapy-naive patients with
advanced or recurrent STS were treated with a combination
of docetaxel, gemcitabine, and bevacizumab [44]. After a
median follow-up of 36 months, the overall RR observed was4 Sarcoma
31.4%. There were 5 complete responses (CRs), 6 PRs, and
18 SDs lasting for a median of 6 months. The combination
treatment was considered safe and the highest-grade adverse
events found were mostly related to bevacizumab.
3. The Insulin-LikeGrowth Factor Pathway
The insulin-like growth factor (IGF) system is a well-known
complex network that regulates growth and development
in superior organisms (Figure 2). The IGF receptor type 1
(IGFR-1) belongs to the family of tyrosine kinase receptors.
The binding of its ligand IGF1 causes its phosphorylation
and the subsequent activation of the downstream pathway
that ﬁnally leads to proliferation and inhibition of apoptosis.
The relationship between the IGF system and sarcomas is
long-time known but the ﬁrst studies to describe it were
merely epidemiological [45]. In the last years, a variety
of studies have conﬁrmed this point. Thus, Prieur et al.
described in 2004 the binding of EWS/FLI1 to the IGFBP3
promoter and the subsequent inhibition of IGFBP3 and the
increase in free IGFR-1 ligand levels, which are related to
the development of this malignancy [46]. Other sarcomas
such as alveolar soft part sarcoma, leiomyosarcoma, synovial
sarcoma, rhabdomyosarcoma, or desmoplastic small round
cell tumor have also been described as tumors in which
increases in IGFR-1 levels or some of its ligands have been
correlated with sarcomagenesis [47–58].
3.1. IGF Pathway Inhibitors. The background described pre-
viously has led to the development of several studies that test
diﬀerentstrategiestoassesstheinhibitionoftheIGFpathway
in sarcoma models in vitro and in vivo [59–67]. The results,
especially in rhabdomyosarcoma and Ewing’s sarcoma, have
been encouraging and the clinical development of these
drugs is currently being carried out.
3.1.1. Anti-IGFR-1 Antibodies. Among the diﬀerent strate-
gies developed to inhibit the IGF pathway, the most promis-
ing results have been achieved with monoclonal antibodies.
There are several phase I studies that assess the safety and
eﬃcacy of inhibiting the IGF system in sarcomas with these
drugs. Thus, Tolcher et al. published in 2009 an early clinical
study with AMG 479, a fully human monoclonal antibody to
IGFR-1. 15 out of 53 patients enrolled were sarcoma patients
(12 Ewing’s sarcoma, 3 others). Interestingly, 1 durable CR
and 1 PR were achieved in 2 patients with Ewing’s sarcoma
[68]. In another phase I study recently published, a cohort of
patients with diﬀerent sarcoma histologies were treated with
ﬁgitumumab (a fully human monoclonal antibody targeting
the IGFR-1). Among 29 patients enrolled, 2 Ewing’s sarcoma
patients had objective responses (1 CR, 1 PR), 6 Ewing’s
sarcoma patients, 1 synovial sarcoma, and 1 ﬁbrosarcoma
achieved SD [69]. Unfortunately, the clinical development of
this drug has been stopped due to disappointing results in
other malignancies.
Several phase II trials with anti-IGFR-1 antibodies are
currently being conducted. Preliminary data of treatment
with IMC-A12 (cixutumumab) in patients with advanced
or metastatic STS and Ewing’s sarcoma have been reported
in the 2011 ASCO Annual Meeting. The best results were
observed in the adipocytic sarcoma arm, with clinical beneﬁt
being achieved in 22 out of 37 patients (1 PR, 21 SD).
Moreover, the PFS at 12 weeks in this group of patients was
50%[70].Withsuchpromisingresults,furtherinvestigations
are warranted.
3.1.2. IGFR-1 TKIs. A number of small molecules that
inhibit IGFR-1 by binding to the tyrosine kinase intracellular
portion of the receptor are currently in clinical development.
No results of eﬃcacy and safety are available yet but there
is a body of preclinical data that support this therapeutic
approach [71–78]. Reports of clinical outcome in patients
treated with these drugs are long awaited and will allow us
to conﬁrm the usefulness of this strategy.
4.The MammalianTarget
RapamycinPathway
The mammalian target of rapamycin (mTOR) is a ser-
ine/threonine kinase integrated in the phosphatidyl-inositol
3-kinase (PI3K) complex network of signaling. It forms part
of 2 multiprotein complexes named mTOR complex 1 and
mTOR complex 2 (mTORC1 and mTORC2) and plays a key
role in cell growth, proliferation, angiogenesis, and survival
(Figure 3). Due to the many functions that mTOR regulates,
its abnormal activity leads to a number of malignancies
including sarcomas. The upregulation of growth factors or
mutations in tyrosine kinase receptors that belongs to the
mTOR network have been reported to be involved in the
development of various sarcomas [79–84]. Furthermore,
deletions of some mTOR pathway tumor suppressors such
as tuberous sclerosis complex 1 and 2 (TSC1 and TSC2) and
neuroﬁbromatosis type 1 (NF1) are associated with both,
benign and malignant mesenchymal tumors [85–88]. Hence,
the capital importance of mTOR in tumorigenesis has made
the development of mTOR inhibitors an important issue in
oncology.
4.1. mTOR Inhibitors. To date, 4 compounds with anti-
mTOR activity have reached the clinical setting. All of
them belong to a single family of drugs and are derived
from an initial molecule called sirolimus (rapamycin). Thus,
temsirolimus, everolimus, ridaforolimus, and the already
mentioned sirolimus are nowadays under investigation in
sarcomas and other tumors. Sirolimus inhibits mTOR kinase
activity by binding to FK506 binding protein (FKBP12),
one of the proteins that form mTORC1. This leads to cell
cycle arresting in G1 phase and the subsequent inhibition in
proliferationandcellgrowth.Preclinical datasuggestactivity
of sirolimus in some paediatric malignancies including
Ewing’s sarcoma, rhabdomyosarcoma, and osteosarcoma
[89, 90]. But, despite preclinical evidences, the only phase
II trial with sirolimus in sarcomas to date (combined with
ciclofosfamide) has been reported as negative [91]. A pro-
drug of sirolimus named temsirolimus has also been tested
in treatment of sarcoma. At least 2 papers have reported
tumor growth inhibition in murine xenograft models ofSarcoma 5
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rhabdomyosarcoma when treated with temsirolimus [92,
93].ButtheﬁrstphaseIItrialpublishedreporteddisappoint-
ing results, with just 2 out of 41 STS patients achieving PR.
Thus, the authors concluded that temsirolimus in patients
with STS has limited clinical activity and signiﬁcant toxicity
[94]. On the other hand, preliminary results of another
phase II trial of temsirolimus in pediatric patients with
neuroblastoma, high-grade glioma, and rhabdomyosarcoma
are slightly more encouraging, with 2 PR (1 neuroblastoma,
1 rhabdomyosarcoma) and 11 SD from a total of 52 patients
[95]. Everolimus is an orally available mTOR inhibitor
developed to be much more soluble than sirolimus. Cell
cycle arrest in diﬀerent tumor models has been observed
with everolimus and even prolonged survival in a murine6 Sarcoma
model of leiomyosarcoma has been reported [96]. The
only preliminary data reported to date of a phase II trial
of everolimus in STS or bone sarcoma showed a clinical
eﬃcacy (CR + PR + SD) of 20% [97]. The last member
of the family of rapamycin analogs (also called rapalogs)
is ridaforolimus. It has a better pharmacokinetic proﬁle,
presenting a more favorable bioavailability than sirolimus.
Activity of ridaforolimus alone has been conﬁrmed in cell
lines and xenograft models of sarcoma. Moreover, additive
inhibitory eﬀects when combined with cytotoxic agents
have also been reported [98]. In the clinical setting, a
phase II trial by Chawla et al. achieved a 29% clinical
beneﬁt in patients with advanced sarcoma treated with
intravenous ridaforolimus and a median OS of 40 weeks
[99]. Such interesting results led to the only phase III trial
to date with an mTOR inhibitor: the SUCCEED trial. This
double-blind, placebo-controlled phase III trial randomized
sarcoma patients who had achieved CR, PR, or SD after
1, 2, or 3 lines of chemotherapy to receive placebo or
ridaforolimus as maintenance treatment. Results recently
reported showed a 28% reduction in the risk of progression
in ridaforolimus arm compared with placebo arm and a
3.1-week improvement in PFS [100]. Mature OS data are
not yet available but everything indicates that ridaforolimus
is a promising drug in treatment of sarcomas and further
investigations are warranted.
A very rare type of mesenchymal malignant tumor
named Perivascular Epithelioid Cell Tumor (PEComa) has
been specially related to the mTOR pathway. Dysfunction
in tumor suppressors TSC1 and 2 and the subsequent
upregulation of mTORC1 seems to be a crucial step in the
development of this disease. Thus, responses with sirolimus
and temosirolimus have been reported in at least 2 studies
[101, 102]. However, another study did not ﬁnd these
positive results, making necessary additional investigations
[103].
All 4 rapalogs described previously belong to a ﬁrst
generation of mTOR inhibitors able to inhibit mTORC1
but not mTORC2. mTORC2 seems to be responsible for
feedback phosphorylation of Akt in the PI3K/Akt pathway,
which could be a possible mechanism of resistance in
sarcomas. So, a new generation of mTOR inhibitors with
activity against mTORC1 and mTORC2 is under early
development in an attempt to block this escape route.
5. SpeciﬁcChromosomal Translocationsas
Therapeutic Targets
About1/3ofsarcomasareassociatedwithspeciﬁcchromoso-
mal translocations. These translocations are an early step in
carcinogenesis, promoting some of the processes that ﬁnally
lead to the appearance of sarcomas [104]. Thus, trying to
inhibit the eﬀects of these genetic alterations seems to be
a reasonable option in ﬁghting sarcomas. Dermatoﬁbrosar-
coma protuberans is an example of this group of sarcomas. It
is characterized by a t(17; 22) translocation that leads to the
overexpression of platelet-derived growth factor B (PDGFB).
Imatinib is a TKI with known activity against the receptor
of PDGFB, PDGFR. Because of that, its eﬃcacy has been
assessed in dermatoﬁbrosarcoma protuberans with excellent
results (46% PR, 25% SD) [105, 106].
Clear cell sarcoma is also associated with a speciﬁc
chromosomal translocation, t(12; 22)(q13; q12) in most of
the cases. One of the consequences of this chromosomal
rearrangement is the activation of the hepatocyte growth
factorreceptor(MET).Thisactivationisinvolvedininvasion
and angiogenesis. A response in a clear cell sarcoma patient
with the MET inhibitor ARQ197 has recently been reported
in a phase II trial, which is especially relevant in this
treatment-resistant disease [107].
But probably the most studied translocation-related
sarcoma is Ewing’s sarcoma. This disease characteristically
has a t(11; 22) translocation that leads to expression of the
oncogenic fusion protein EWS/FLI1. This chimerical protein
is involved in Ewing’s sarcoma development since it acts as
an oncogenic transcription factor but needs binding to other
proteins such as RNA helicase A for its oncogenic function.
Recently described YK-4-279, a new compound that blocks
RNA helicase A binding to EWS/FLI1, induces apoptosis
in Ewing’s sarcoma cell lines and reduces tumor growth in
orthotopic xenografts [108]. A clinical trial to assess the
eﬃcacy of this new drug is planned.
6. Virotherapy
One of the most innovative approaches in cancer treatment
developed in the last years is oncolytic virotherapy. The
general basis of this strategy is that the therapeutic virus is
capable to recognize speciﬁcally tumor cells, replicate into
them, and lead to their death without damaging normal
cells. A paper recently published in Nature by Breitbach
et al. assessed the safety and eﬃcacy of an intravenous
delivery of an oncolytic poxvirus in humans. Treatment
was generally well tolerated and the only sarcoma patient
enrolled (a 55-year-old female with a heavily pretreated
advanced leiomyosarcoma) achieved SD by RECIST criteria
for >16 weeks [109]. This result is as encouraging for
sarcoma treatment as a 2010 study published by Li et al.
In that paper, the authors reported marked cytolysis and
apoptosis in osteosarcoma cell lines in vitro and signiﬁcant
tumor growth suppression in a human osteosarcoma murine
xenograft model when treated with a telomerase-speciﬁc
oncolytic adenovirus [110]. More in-deep preclinical and
clinical investigations are needed but virotherapy seems
a feasible and reasonable option in future treatments for
sarcomas.
7.CombinedTargetedTherapies
Although clinical experience with targeted therapies in
sarcomas as single treatment is short, there are some
published studies with combination of 2 of these drugs. The
most studied double-inhibition-targeted therapies are those
related with IGFR-1 pathway, with preclinical evidences
of activity in sarcoma models [111–113]. Based on these
studies, at least 2 phase I trials have been reported, oneSarcoma 7
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of them with ﬁgitumumab and everolimus in advanced
sarcoma patients and the other solid tumors and the other
with cixutumumab combined with temsirolimus in Ewing’s
sarcoma patients that is currently enrolling [114, 115].
Both studies reported good toxicity proﬁles, making the
combination of 2 targeted therapies an attractive and safe
option to be developed. Most trials involving the targeted
therapies reviewed in this paper are summarized in Table 1.
8.FuturePerspectives
An increasing number of new targets in treatment of
sarcomas are being identiﬁed in the last years. The ﬁnding of
new important key eﬀectors in sarcomas biology has resulted
in a growing development of inhibitor drugs that need
to be tested. For instance, increased activity in Hedgehog
pathway has recently been reported in certain sarcomas such
as rhabdomyosarcoma, osteosarcoma, chondrosarcoma, and
Ewing’s sarcoma [117–121]. Other reports suggest that
rhabdomyosarcoma and osteosarcoma aggressiveness seems
to be related with Notch signalling pathway [122, 123]. This
has led to the conduction of a clinical trial with Hedgehog
and Notch inhibitors with no results to date.
Anaplastic lymphoma kinase (ALK) is another protein
recently related to sarcomas that is upregulated in approxi-
mately 50% of cases of inﬂammatory myoﬁbroblastic tumor.
Interestingly, in a phase I trial with the ALK inhibitor
crizotinib, a patient with ALK overexpression related to
inﬂammatory myoﬁbroblastic tumor experienced a durable
PR [116].
Histone deacetylase (HDAC) inhibitors have also shown
signs of eﬃcacy in preclinical models of sarcomas [124–128]
and several clinical trials are currently ongoing.
PI3K/mTOR dual-inhibitor NVP-BEZ235 that induces
G1 cell cycle arrest in sarcomas in vitro and in vivo [129]h a s
been identiﬁed as well as a brand new promising agent.
Other molecules such as MDM2 and protein families
BCL-2 and CDKs have been described lately as associ-
ated with sarcomas [130–132]. Future investigations with
inhibitors are warranted.
9. Conclusions
Despite the low incidence of sarcomas in general popula-
tion regarding other types of cancer, the ﬁnding of new
active treatments is essential since it is a rarely curable
disease. Hence, a rapidly increasing number of targeted
therapies have been developed in the last years with diﬀerent
results. In general, most of these treatments do not achieve
signiﬁcant tumor shrinkage and SD is usually the best
response reported. In addition, OS has not been dramatically
increased in the majority of these patients, showing the
necessityofkeepworking.Inanattempttoimproveresponse
rates, one of the strategies that are currently ongoing is
the combination treatment with targeted therapies and
conventional cytotoxic drugs. Toxicity is an important issue
when using this approach and more clinical trials are needed
to assess the safety of this therapeutic option. Combinations
of more than one targeted agent are another reasonable
choice. The strategy of inhibiting a signalling pathway and
simultaneously others that could be possible ways of escape
is an attractive alternative still under early development.
Phase I trials reported to date with 2 targeted therapies show
favourable toxicity proﬁles, making this strategy a feasible
and promising issue to be explored. Diﬀerent approaches
like those, future identiﬁcation of new pathways and their
correspondent inhibitors and the arise of innovative agents
such as oncolytic viruses, make the ﬁnal endpoint of cure
sarcsomas a goal not so far to be reached.
Acknowledgments
L. Lagares-Tena is funded by the Comissionat per a Univer-
sitats i Recerca (CUR) from Departament d’Innovaci´ o, Uni-
versitats i Empresa (DIUE) de la Generalitat de Catalunya i
delFonsSocialEuropeu.FigureswereproducedusingServier
Medical Art. The work in the Sarcoma Research Group
is supported by grants from the Fondo de Investigaciones
Sanitarias-ISCIII (CP06/00151; PI08/0259; PI11/00038) and
from the Ministerio de sanidad y Consumo (TRA-163).
References
[1] A. Italiano, S. Mathoulin-Pelissier, A. Le Cesne et al., “Trends
in survival for patients with metastatic soft-tissue sarcoma,”
Cancer, vol. 117, no. 5, pp. 1049–1054, 2011.
[ 2 ] P .G .C a s a l ia n dJ .Y .B l a y ,“ E S M O / C O N T I C A N E T /
EUROBONET Consensus Panel of experts. Soft tissue sar-
comas: ESMO Clinical Practice Guidelines for diagnosis,
treatment and follow-up,” Annals of Oncology, vol. 21,
supplement 5, pp. v198–v203, 2010.
[3] E.Wardelmann,H.U.Schildhaus,S.Merkelbach-Bruseetal.,
“Soft tissue sarcoma: from molecular diagnosis to selection
of treatment. Pathological diagnosis of soft tissue sarcoma
amid molecular biology and targeted therapies,” Annals of
Oncology, vol. 21, no. 7, pp. vii265–vii269, 2010.
[ 4 ]R .K .J a i n ,D .G .D u d a ,J .W .C l a r k ,a n dJ .S .L o e ﬄer,
“Lessons from phase III clinical trials on anti-VEGF therapy
for cancer,” Nature Clinical Practice Oncology, vol. 3, no. 1,
pp. 24–40, 2006.
[ 5 ] N .F e r r a r a ,“ V a s c u l a re n d o t h e l i a lg r o wt hf a c t o r:b a s i cs c i e n c e
and clinical progress,” Endocrine Reviews,v o l .2 5 ,n o .4 ,p p .
581–611, 2004.
[6] N. Ferrara, “VEGF-A: a critical regulator of blood vessel
growth,” European Cytokine Network, vol. 20, no. 4, pp. 158–
163, 2009.
[7] J. A. Nagy, A. M. Dvorak, and H. F. Dvorak, “VEGF-A and
the induction of pathological angiogenesis,” Annual Review
of Pathology, vol. 2, pp. 251–275, 2007.
[8] A. Potti, A. K. Ganti, K. Tendulkar et al., “Determination
of vascular endothelial growth factor (VEGF) overexpression
in soft tissue sarcomas and the role of overexpression in
leiomyosarcoma,” Journal of Cancer Research and Clinical
Oncology, vol. 130, no. 1, pp. 52–56, 2004.
[9] U. Graeven, N. Andre, E. Achilles, C. Zornig, and W.
Schmiegel, “Serum levels of vascular endothelial growth
factor and basic ﬁbroblast growth factor in patients with
soft-tissue sarcoma,” Journal of Cancer Research and Clinical
Oncology, vol. 125, no. 10, pp. 577–581, 1999.Sarcoma 9
[ 1 0 ]C .C h a o ,T .A l - S a l e e m ,J .J .B r o o k s ,A .R o g a t k o ,W .G .
Kraybill, and B. Eisenberg, “Vascular endothelial growth
factor and soft tissue sarcomas: tumor expression correlates
with grade,” Annals of Surgical Oncology, vol. 8, no. 3, pp.
260–267, 2001.
[11] A. Iyoda, K. Hiroshima, M. Baba, T. Fujisawa, T. Yusa, and H.
Ohwada, “Expression of vascular endothelial growth factor
in thoracic sarcomas,” Annals of Thoracic Surgery, vol. 71, no.
5, pp. 1635–1639, 2001.
[12] K. Shintani, A. Matsumine, K. Kusuzaki et al., “Expression
of hypoxia-inducible factor (HIF)-1α as a biomarker of
outcome in soft-tissue sarcomas,” Virchows Archiv, vol. 449,
no. 6, pp. 673–681, 2006.
[13] A. Comandone, A. Boglione, E. Berardengo et al., “Microves-
sel density (MVD) as a marker of neoangiogenesis: prog-
nostic signiﬁcance in correlation to grading and stage
in adult soft tissue sarcoma (STS) of the extremities. A
perspective study,” Proceedings of the American Society of
Clinical Oncology, vol. 22, abstract 3303, 2003.
[14] C.C.W est,N.J .Bro wn,D .C.M angham,R.J .Grimer ,andM.
W.R.Reed,“Microvesseldensitydoesnotpredictoutcomein
high grade soft tissue sarcoma,” European Journal of Surgical
Oncology, vol. 31, no. 10, pp. 1198–1205, 2005.
[15] N. C. Saenz, M. J. Heslin, V. Adsay et al., “Neovascularity
and clinical outcome in high-grade extremity soft tissue
sarcomas,” Annals of Surgical Oncology, vol. 5, no. 1, pp. 48–
53, 1998.
[16] K. Yudoh, M. Kanamori, K. Ohmori, T. Yasuda, M. Aoki, and
T. Kimura, “Concentration of vascular endothelial growth
factorinthetumourtissueasaprognosticfactorofsofttissue
sarcomas,”BritishJournalofCancer,vol.84,no.12,pp.1610–
1615, 2001.
[17] S. Stacchiotti, E. Tamborini, A. Marrari et al., “Response
to sunitinib malate in advanced alveolar soft part sarcoma,”
Clinical Cancer Research, vol. 15, no. 3, pp. 1096–1104, 2009.
[18] S. George, P. Merriam, R. G. Maki et al., “Multicenter phase
II trial of sunitinib in the treatment of nongastrointestinal
stromal tumor sarcomas,” Journal of Clinical Oncology, vol.
27, no. 19, pp. 3154–3160, 2009.
[19] S. T. Mahmood, S. Agresta, C. Vigil et al., “Phase II study of
sunitinib malate, a multi-targeted tyrosine kinase inhibitor
in patients with relapsed or refractory soft tissue sarcomas.
Focus on 3 prevalent histologies: Leiomyosarcoma, liposar-
coma, and malignant ﬁbrous histiocytoma,” International
Journal of Cancer, vol. 129, pp. 1963–1969, 2010.
[20] M. L. Hensley, M. W. Sill, D. R. Scribner et al., “Sunitinib
malate in the treatment of recurrent or persistent uterine
leiomyosarcoma: a Gynecologic Oncology Group phase II
study,” Gynecologic Oncology, vol. 115, no. 3, pp. 460–465,
2009.
[21] X. Lu, X. Tang, W. Guo, T. Ren, and H. Zhao, “Sorafenib
induces growth inhibition and apoptosis of human chon-
drosarcoma cells by blocking the RAF/ERK/MEK pathway,”
Journal of Surgical Oncology, vol. 102, no. 7, pp. 821–826,
2010.
[22] Y. Pignochino, G. Grignani, G. Cavalloni et al., “Sorafenib
blocks tumourgrowth, angiogenesis and metastatic potential
in preclinical models of osteosarcoma through a mechanism
potentially involving the inhibition of ERK1/2, MCL-1 and
ezrin pathways,” Molecular Cancer, vol. 8, article 118, 2009.
[23] W. Maruwge, P. D’Arcy, A. Folin et al., “Sorafenib inhibits
tumor growth and vascularization of rhabdomyosarcoma
cells by blocking IGF-1R-mediated signaling,” OncoTargets
and Therapy, vol. 1, pp. 67–78, 2008.
[24] C. L. Peng, W. Guo, T. Ji et al., “Sorafenib induces growth
inhibition and apoptosis in human synovial sarcoma cells
via inhibiting the RAF/MEK/ERK signaling pathway,” Cancer
Biology and Therapy, vol. 8, no. 18, pp. 1729–1736, 2009.
[25] G. Ambrosini, H. S. Cheema, S. Seelman et al., “Sorafenib
inhibits growth and mitogen-activated protein kinase signal-
ing in malignant peripheral nerve sheath cells,” Molecular
Cancer Therapeutics, vol. 7, no. 4, pp. 890–896, 2008.
[26] A. Ardavanis, D. Doufexis, P. Kountourakis, and G.
Rigatos, “A Kaposi’s sarcoma complete clinical response after
sorafenib administration,” Annals of Oncology, vol. 19, no. 9,
pp. 1658–1659, 2008.
[27] U.Basso,A.Brunello,A.Bertuzzi,andA.Santoro,“Sorafenib
is active on lung metastases from synovial sarcoma,” Annals
of Oncology, vol. 20, no. 2, pp. 386–387, 2009.
[ 2 8 ]R .G .M a k i ,D .R .D ’ A d a m o ,M .L .K e o h a ne ta l . ,“ P h a s eI I
study of sorafenib in patients with metastatic or recurrent
sarcomas,” Journal of Clinical Oncology, vol. 27, no. 19, pp.
3133–3140, 2009.
[29] G. Grignani, E. Palmerini, P. Dileo et al., “A phase II
trial of sorafenib in relapsed and unresectable high-grade
osteosarcoma after failure of standard multimodal therapy:
an ItalianSarcoma Group study,” Annals of Oncology, vol. 23,
pp. 508–516, 2012.
[30] M. Von Mehren, C. Rankin, J. R. Goldblum et al., “Phase
2 Southwest Oncology Group-directed intergroup trial
(S0505) of sorafenib in advanced soft tissue sarcomas,”
Cancer, vol. 118, pp. 770–776, 2012.
[31] S.Pacey,M.J.Ratain,K.T.Flahertyetal.,“Eﬃcacyandsafety
of sorafenib in a subset of patients with advanced soft tissue
sarcoma from a phase II randomized discontinuation trial,”
Investigational New Drugs, vol. 29, no. 3, pp. 481–488, 2011.
[32] S. Sleijfer, I. Ray-Coquard, Z. Papai et al., “Pazopanib, a
multikinase angiogenesis inhibitor, in patients with relapsed
or refractory advanced soft tissue sarcoma: a phase II study
from the European organisation for research and treatment
of cancer-soft tissue and bone sarcoma group (EORTC Study
62043),” Journal of Clinical Oncology, vol. 27, no. 19, pp.
3126–3132, 2009.
[33] W Van-der-Graaf, J. Blay, S. P. Chawla et al., “PALETTE:
a randomized, double-blind, phase III trial of pazopanib
versus placebo in patients (pts) with soft-tissue sarcoma
(STS) whose disease has progressed during or following
prior chemotherapy—an EORTC STBSG Global Network
Study (EORTC 62072),” Journal of Clinical Oncology, vol. 29,
abstract LBA10002, 2011.
[34] A.C.Shor,E.A.Keschman,F.Y.Leeetal.,“Dasatinibinhibits
migration and invasion in diverse human sarcoma cell lines
and induces apoptosis in bone sarcoma cells dependent on
Src kinase for survival,” Cancer Research,v o l .6 7 ,n o .6 ,p p .
2800–2808, 2007.
[35] F. Timeus, N. Crescenzio, A. Fandi, A. Doria, L. Foglia,
and L. C. di Montezemolo, “In vitro antiproliferative and
antimigratory activity of dasatinib in neuroblastoma and
Ewing sarcoma cell lines,” Oncology Reports,v o l .1 9 ,n o .2 ,
pp. 353–359, 2008.
[36] P. Hingorani, W. Zhang, R. Gorlick, and E. A. Kolb,
“InhibitionofSrcphosphorylationaltersmetastaticpotential
of osteosarcoma in vitro but not in vivo,” Clinical Cancer
Research, vol. 15, no. 10, pp. 3416–3422, 2009.
[37] Y. M. Schrage, I. H. Briaire-de Bruijn, N. F. C. C. De Miranda
et al., “Kinome proﬁling of chondrosarcoma reveals Src-
pathway activity and dasatinib as option for treatment,”
Cancer Research, vol. 69, no. 15, pp. 6216–6222, 2009.10 Sarcoma
[38] S. Dalal, A. M. Berry, C. J. Cullinane et al., “Vascular
endothelial growth factor: a therapeutic target for tumors of
the Ewing’s sarcoma Family,” Clinical Cancer Research, vol.
11, no. 6, pp. 2364–2378, 2005.
[39] A. Ferrario and C. J. Gomer, “Avastin enhances photody-
namic therapy treatment of Kaposi’s sarcoma in a mouse
tumormodel,”JournalofEnvironmentalPathology,Toxicology
and Oncology , vol. 25, pp. 251–259, 2006.
[40] D. T. Vistica, M. Hollingshead, S. D. Borgel et al., “Ther-
apeutic vulnerability of an in vivo model of alveolar soft
part sarcoma (ASPS) to antiangiogenic therapy,” Journal of
Pediatric Hematology/Oncology, vol. 31, no. 8, pp. 561–570,
2009.
[41] A.L.M yers,R.F .W illiams,C.Y .Ng,J .E.Hartwich,andA.M.
Davidoﬀ,“Bevacizumab-inducedtumorvesselremodelingin
rhabdomyosarcoma xenografts increases the eﬀectiveness of
adjuvant ionizing radiation,” Journal of Pediatric Surgery, vol.
45, no. 6, pp. 1080–1085, 2010.
[42] Y. Okada, T. Akisue, H. Hara et al., “The eﬀect of beva-
cizumab on tumour growth of malignant ﬁbrous histiocy-
toma in an animal model,” Anticancer Research, vol. 30, no.
9, pp. 3391–3395, 2010.
[43] D. R. D’Adamo, S. E. Anderson, K. Albritton et al., “Phase
II study of doxorubicin and bevacizumab for patients with
metastatic soft-tissue sarcomas,” Journal of Clinical Oncology,
vol. 23, no. 28, pp. 7135–7142, 2005.
[44] C. F. Verschraegen, H. Arias-Pulido, S. J. Lee et al., “Phase
IB study of the combination of docetaxel, gemcitabine, and
bevacizumab in patients with advanced or recurrent soft
tissue sarcoma: the Axtell regimen,” Annals of Oncology, vol.
23, pp. 785–790, 2011.
[45] R. Gorlick, P. Anderson, I. Andrulis et al., “Biology of
childhood osteogenic sarcoma and potential targets for ther-
apeutic development: Meeting Summary,” Clinical Cancer
Research, vol. 9, no. 15, pp. 5442–5453, 2003.
[46] A. Prieur, F. Tirode, P. Cohen, and O. Delattre, “EWS/FLI-1
silencingandgeneproﬁlingofEwingcellsrevealdownstream
oncogenic pathways and a crucial role for repression of
insulin-like growth factor binding protein 3,” Molecular and
Cellular Biology, vol. 24, no. 16, pp. 7275–7283, 2004.
[ 4 7 ]J .K h a n ,M .L .B i t t n e r ,L .H .S a a le ta l . ,“ c D N Am i c r o a r r a y s
detect activation of a myogenic transcription program by the
PAX3-FKHR fusion oncogene,” Proceedings of the National
Academy of Sciences of the United States of America, vol. 96,
no. 23, pp. 13264–13269, 1999.
[48] D. Ayalon, T. Glaser, and H. Werner, “Transcriptional
regulation of IGF-I receptor gene expression by the PAX3-
FKHR oncoprotein,” Growth Hormone and IGF Research, vol.
11, no. 5, pp. 289–297, 2001.
[49] E. Karnieli, H. Werner, F. J. Rauscher, L. E. Benjamin,
and D. Leroith, “The IGF-I receptor gene promoter is a
molecular target for the Ewing’s sarcoma-Wilms’ tumor 1
fusion protein,” Journal of Biological Chemistry, vol. 271, no.
32, pp. 19304–19309, 1996.
[50] I. Finkeltov, S. Kuhn, T. Glaser et al., “Transcriptional regu-
lation of IGF-I receptor gene expression by novel isoforms of
the EWS-WT1 fusion protein,” Oncogene, vol. 21, no. 12, pp.
1890–1898, 2002.
[ 5 1 ]H .W e r n e r ,G .I d e l m a n ,M .R u b i n s t e i n ,P .P a t t e e ,S .R .
N a g a l l a ,a n dC .T .R o b e r t s ,“ An o v e lE W S - W T 1g e n ef u s i o n
product in desmoplastic small round cell tumor is a potent
transactivator of the insulin-like growth factor-I receptor
(IGF-IR) gene,” Cancer Letters, vol. 247, no. 1-2, pp. 84–90,
2007.
[52] P. V. Pedone, R. Tirabosco, A. O. Cavazzana et al., “Mono-
and bi-allelic expression of insulin-like growth factor II gene
in human muscle tumors,” Human Molecular Genetics, vol. 3,
no. 7, pp. 1117–1121, 1994.
[53] H. Scrable, W. Cavenee, F. Ghavimi, M. Lovell, K. Morgan,
and C. Sapienza, “A model for embryonal rhabdomyosar-
coma tumorigenesis that involves genome imprinting,” Pro-
ceedings of the National Academy of Sciences of the United
States of America, vol. 86, no. 19, pp. 7480–7484, 1989.
[54] M. Visser, C. Sijmons, J. Bras et al., “Allelotype of pediatric
rhabdomyosarcoma,” Oncogene, vol. 15, no. 11, pp. 1309–
1314, 1997.
[55] S. Zhan, D. N. Shapiro, and L. J. Helman, “Activation
of an imprinted allele of the insulin-like growth factor II
gene implicated in rhabdomyosarcoma,” Journal of Clinical
Investigation, vol. 94, no. 1, pp. 445–448, 1994.
[56] J. Anderson, A. Gordon, K. Pritchard-Jones et al., “Genes,
chromosomes, and rhabdomyosarcoma,” Genes Chromo-
somes Cancer, vol. 26, pp. 275–285, 1999.
[ 5 7 ]Y .S u n ,D .G a o ,Y .L i u ,J .H u a n g ,S .L e s s n i c k ,a n dS .T a n a k a ,
“IGF2 is critical for tumorigenesis by synovial sarcoma
oncoprotein SYT-SSX1,” Oncogene, vol. 25, no. 7, pp. 1042–
1052, 2006.
[58] D. R. H. De Bruijn, S. V. Allander, A. H. A. Van Dijk et al.,
“The synovial sarcoma-associated SS18-SSX2 fusion protein
inducesepigeneticgene(de)regulation,”CancerResearch,vol.
66, no. 19, pp. 9474–9482, 2006.
[59] D. N. Shapiro, B. G. Jones, L. H. Shapiro, P. Dias, and P.
J. Houghton, “Antisense-mediated reduction in insulin-like
growth factor-I receptor expression suppresses the malignant
phenotype of a human alveolar rhabdomyosarcoma,” Journal
of Clinical Investigation, vol. 94, no. 3, pp. 1235–1242, 1994.
[60] K. Scotlandi, S. Avnet, S. Benini et al., “Expression of an
IGF-I receptor dominant negative mutant induces apoptosis,
inhibits tumorigenesis and enhances chemosensitivity in
Ewing’s sarcoma cells,” International Journal of Cancer, vol.
101, no. 1, pp. 11–16, 2002.
[61] K. Scotlandi, S. Benini, P. Nanni et al., “Blockage of insulin-
like growth factor-I receptor inhibits the growth of Ewing’s
sarcoma in athymic mice,” Cancer Research, vol. 58, no. 18,
pp. 4127–4131, 1998.
[62] E. Anders Kolb, R. Gorlick, P. J. Houghton et al., “Initial
testing (stage 1) of a monoclonal antibody (SCH 717454)
against the IGF-1 receptor by the pediatric preclinical testing
program,” Pediatric Blood and Cancer,v o l .5 0 ,n o .6 ,p p .
1190–1197, 2008.
[63] T. Kalebic, M. Tsokos, and L. J. Helman, “In vivo treatment
with antibody against IGF-1 receptor suppresses growth of
human rhabdomyosarcoma and down-regulates p34(cdc2),”
Cancer Research, vol. 54, no. 21, pp. 5531–5534, 1994.
[64] K. Scotlandi, M. C. Manara, G. Nicoletti et al., “Antitumor
activity of the insulin-like growth factor-I receptor kinase
inhibitor NVP-AEW541 in musculoskeletal tumors,” Cancer
Research, vol. 65, no. 9, pp. 3868–3876, 2005.
[65] A. S. Martins, C. Mackintosh, D. Herrero Mart´ ın et al.,
“Insulin-like growth factor I receptor pathway inhibition by
ADW742, alone or in combination with imatinib, doxoru-
bicin,orvincristine,isanoveltherapeuticapproachinEwing
tumor,” Clinical Cancer Research, vol. 12, no. 11 I, pp. 3532–
3540, 2006.
[66] M.C.Manara,L.Landuzzi,P.Nannietal.,“Preclinicalinvivo
study of new insulin-like growth factor-I receptor-speciﬁc
inhibitor in Ewing’s sarcoma,” Clinical Cancer Research, vol.
13, no. 4, pp. 1322–1330, 2007.Sarcoma 11
[67] L. Cao, Y. Yu, I. Darko et al., “Addiction to elevated insulin-
like growth factor I receptor and initial modulation of the
AKT pathway deﬁne the responsiveness of rhabdomyosar-
coma to the targeting antibody,” Cancer Research, vol. 68, no.
19, pp. 8039–8048, 2008.
[68] A. W. Tolcher, J. Sarantopoulos, A. Patnaik et al., “Phase I,
pharmacokinetic, and pharmacodynamic study of AMG 479,
a fully human monoclonal antibody to insulin-like growth
factor receptor 1,” Journal of Clinical Oncology, vol. 27, no.
34, pp. 5800–5807, 2009.
[69] D. Olmos, S. Postel-Vinay, L. R. Molife et al., “Safety,
pharmacokinetics, and preliminary activity of the anti-IGF-
1R antibody ﬁgitumumab (CP-751,871) in patients with
sarcoma and Ewing’s sarcoma: a phase 1 expansion cohort
study,”TheLancetOncology,vol.11,no.2,pp.129–135,2010.
[70] P. Schoﬀski, D. Adkins, J. Blay et al., “Phase II trial of anti-
IGF-IR antibody cixutumumab in patients with advanced or
metastatic soft-tissue sarcoma and Ewing family of tumors,”
Journal of Clinical Oncology, vol. 29, abstract 10004, 2011.
[71] K. Scotlandi, M. C. Manara, G. Nicoletti et al., “Antitumor
activity of the insulin-like growth factor-I receptor kinase
inhibitor NVP-AEW541 in musculoskeletal tumors,” Cancer
Research, vol. 65, no. 9, pp. 3868–3876, 2005.
[72] A. S. Martins, C. Mackintosh, D. Herrero Mart´ ın et al.,
“Insulin-like growth factor I receptor pathway inhibition by
ADW742, alone or in combination with imatinib, doxoru-
bicin,orvincristine,isanoveltherapeuticapproachinEwing
tumor,” Clinical Cancer Research, vol. 12, no. 11 I, pp. 3532–
3540, 2006.
[73] M.C.Manara,L.Landuzzi,P.Nannietal.,“Preclinicalinvivo
study of new insulin-like growth factor-I receptor-speciﬁc
inhibitor in Ewing’s sarcoma,” Clinical Cancer Research, vol.
13, no. 4, pp. 1322–1330, 2007.
[74] P. Sabbatini, J. L. Rowand, A. Groy et al., “Antitumor activity
of GSK1904529A, a small-molecule inhibitor of the insulin-
like growth factor-I receptor tyrosine kinase,” Clinical Cancer
Research, vol. 15, no. 9, pp. 3058–3067, 2009.
[75] P. Sabbatini, S. Korenchuk, J. L. Rowand et al.,
“GSK1838705A inhibits the insulin-like growth factor-1
receptor and anaplastic lymphoma kinase and shows
antitumor activity in experimental models of human
cancers,” Molecular Cancer Therapeutics, vol. 8, no. 10, pp.
2811–2820, 2009.
[76] F. Huang, A. Greer, W. Hurlburt et al., “The mechanisms
of diﬀerential sensitivity to an insulin-like growth factor-1
receptor inhibitor (BMS-536924) and rationale for combin-
ing with EGFR/HER2 inhibitors,” Cancer Research, vol. 69,
no. 1, pp. 161–170, 2009.
[77] N. Friedrichs, J. K¨ uchler, E. Endl et al., “Insulin-like growth
factor-1 receptor acts as a growth regulator in synovial
sarcoma,” Journal of Pathology, vol. 216, no. 4, pp. 428–439,
2008.
[78] Z. Duan, E. Choy, D. Harmon et al., “Insulin-like growth
factor-I receptor tyrosine kinase inhibitor cyclolignan
picropodophyllin inhibits proliferation and induces apopto-
sis in multidrug resistant osteosarcoma cell lines,” Molecular
Cancer Therapeutics, vol. 8, no. 8, pp. 2122–2130, 2009.
[79] X. Wan and L. J. Helman, “The biology behind mTOR
inhibition in sarcoma,” Oncologist, vol. 12, no. 8, pp. 1007–
1018, 2007.
[80] A. A. Samani, S. Yakar, D. LeRoith, and P. Brodt, “The role
of the IGF system in cancer growth and metastasis: overview
andrecentinsights,”EndocrineReviews,vol.28,no.1,pp.20–
47, 2007.
[81] Y. Xie, B. Skytting, G. Nilsson, B. Brodin, and O. Larsson,
“Expression of insulin-like growth factor-1 receptor in
synovial sarcoma: association with an aggressive phenotype,”
Cancer Research, vol. 59, no. 15, pp. 3588–3591, 1999.
[82] L. Girnita, A. Girnita, M. Wang, J. M. Meis-Kindblom, L. G.
Kindblom, and O. Larsson, “A link between basic ﬁbroblast
growth factor (bFGF) and EWS/FLI-1 in Ewing’s sarcoma
cells,” Oncogene, vol. 19, no. 37, pp. 4298–4301, 2000.
[ 8 3 ]D .P .M .H u g h e s ,D .G .T h o m a s ,T .J .G i o r d a n o ,L .H .B a k e r ,
and K. T. McDonagh, “Cell surface expression of epidermal
growth factor receptor and her-2 with nuclear expression of
Her-4inprimaryosteosarcoma,”CancerResearch,vol.64,no.
6, pp. 2047–2053, 2004.
[84] R. Ganti, S. X. Skapek, J. Zhang et al., “Expression and
genomic status of EGFR and ErbB-2 in alveolar and embry-
onal rhabdomyosarcoma,” Modern Pathology, vol. 19, no. 9,
pp. 1213–1220, 2006.
[85] J. R. Sampson, “Therapeutic targeting of mTOR in tuberous
sclerosis,” Biochemical Society Transactions,v o l .3 7 ,n o .1 ,p p .
259–264, 2009.
[86] S. Umeoka, T. Koyama, Y. Miki, M. Akai, K. Tsutsui, and
K. Togashi, “Pictorial review of tuberous sclerosis in various
organs,” Radiographics, vol. 28, no. 7, article e32, 2008.
[87] K.P .Boyd,B.R.K orf,andA.Theos,“N euroﬁbromatosistype
1,” Journal of the American Academy of Dermatology, vol. 61,
no. 1, pp. 1–14, 2009.
[88] D. Katz, A. Lazar, and D. Lev, “Malignant peripheral nerve
sheathtumour(MPNST):theclinicalimplicationsofcellular
signalling pathways,” Expert Reviews in Molecular Medicine,
vol. 11, p. e30, 2009.
[89] S. Mateo-Lozano, P. C. Gokhale, V. Soldatenkov, A.
Dritschilo, O. M. Tirado, and V. Notario, “Combination
therapy targeting EWS/FLI-1 oncogene induces apoptosis of
Ewing’s sarcoma cells in vitro and inhibits tumor growth in
vivo,” Clinical Cancer Research, vol. 12, pp. 6781–6790, 2006.
[90] P. J. Houghton, C. L. Morton, R. Gorlick et al., “Stage 2
combination testing of rapamycin with cytotoxic agents by
the pediatric preclinical testing program,” Molecular Cancer
Therapeutics, vol. 9, no. 1, pp. 101–112, 2010.
[91] S. Schuetze, L. Zhao, and R. Chugh, “Results of a phase II
trial of sirolimus (S) and cyclophosphamide (C) in advanced
sarcoma ,” Journal of Clinical Oncology, vol. 29, Abstract
10003, 2011.
[92] L. Dudkin, M. B. Dilling, P. J. Cheshire et al., “Biochemical
correlates of mTOR inhibition by the rapamycin ester CCI-
779 and tumor growth inhibition,” Clinical Cancer Research,
vol. 7, no. 6, pp. 1758–1764, 2001.
[93] X. Wan, N. Shen, A. Mendoza, C. Khanna, and L. J. Helman,
“CCI-779 inhibits rhabdomyosarcoma xenograft growth by
an antiangiogenic mechanism linked to the targeting of
mTOR/Hif-1α/VEGF signaling,” Neoplasia, vol. 8, no. 5, pp.
394–401, 2006.
[94] S.Okuno,H.Bailey,M.R.Mahoneyetal.,“Aphase2studyof
temsirolimus(CCI-779)inpatientswithsofttissuesarcomas:
a study of the mayo phase 2 Consortium (P2C),” Cancer, vol.
117, no. 15, pp. 3468–3475, 2011.
[95] B. Geoerger, M. W. Kieran, S. Grupp et al., “Phase II
study of temsirolimus in children with high-grade glioma,
neuroblastoma, and rhabdomyosarcoma,” Journal of Clinical
Oncology, vol. 28, no. 15S, abstract 9541, 2010.
[96] E. Hernando, E. Charytonowicz, M. E. Dudas et al., “The
AKT-mTOR pathway plays a critical role in the development
of leiomyosarcomas,” Nature Medicine, vol. 13, no. 6, pp.
748–753, 2007.12 Sarcoma
[97] S. Richter, D. Pink, P. Hohenberger et al., “Multicenter,
triplearm, single-stage, phase II trial to determine the
eﬃcacy and safety of everolimus (RAD001) in patients with
refractory bone or soft tissue sarcomas including GIST,”
Journal of Clinical Oncology , vol. 28, no. 15S, abstract 10038,
2010.
[98] R. M. Squillace, D. Miller, M. Cookson et al., “Antitumor
activityofridaforolimusandpotentialcellcycledeterminants
of sensitivity in sarcoma and endometrial cancer models,”
Molecular Cancer Therapeutics, vol. 10, pp. 1959–1968, 2011.
[ 9 9 ]S .P .C h a w l a ,A .P .S t a d d o n ,L .H .B a k e re ta l . ,“ P h a s e
II study of the mammalian target of rapamycin inhibitor
ridaforolimus in patients with advanced bone and soft tissue
sarcomas,” Journal of Clinical Oncology, vol. 30, no. 1, pp. 78–
84, 2012.
[100] S. P. Chawla, J. Blay, I. L. Ray-Coquard et al., “Results of the
phase III, placebo-controlled trial (SUCCEED) evaluating
the mTOR inhibitor ridaforolimus (R) as maintenance
therapy in advanced sarcoma patients (pts) following clinical
beneﬁt from prior standard cytotoxic chemotherapy (CT),”
Annals of Oncology, vol. 29, abstract 10005, 2011.
[101] A. J. Wagner, I. Malinowska-Kolodziej, J. A. Morgan et
al., “Clinical activity of mTOR inhibition with sirolimus in
malignant perivascular epithelioid cell tumors: targeting the
pathogenic activation of mTORC1 in tumors,” Journal of
Clinical Oncology, vol. 28, no. 5, pp. 835–840, 2010.
[102] A. Italiano, C. Delcambre, I. Hostein et al., “Treatment with
the mTOR inhibitor temsirolimus in patients with malignant
PEComa perivascular epithelioid cell tumors (PEComas) are
rare,” Annals of Oncology, vol. 21, no. 5, pp. 1135–1137, 2010.
[103] V.Subbiah,J.C.Trent,andR.Kurzrock,“Resistancetomam-
malian target of rapamycin inhibitor therapy in perivascular
epithelioid cell tumors,” Journal of Clinical Oncology, vol. 28,
no. 24, p. e415, 2010.
[104] M. S´ ainz-Jaspeado, J. Martin-Liberal, L. Lagares-Tena, S.
Mateo-Lozano, X. Garcia-del-Muro, and O. M. Tirado,
“Caveolin-1 in sarcomas: friend or foe?” Oncotarget, vol. 2,
pp. 305–312, 2011.
[105] G. A. McArthur, G. D. Demetri, A. Van Oosterom et
al., “Molecular and clinical analysis of locally advanced
dermatoﬁbrosarcoma protuberans treated with imatinib:
imatinib target exploration consortium study B2225,” Jour-
nal of Clinical Oncology, vol. 23, no. 4, pp. 866–873, 2005.
[106] P. Rutkowski, M. Van Glabbeke, C. J. Rankin et al., “Imatinib
mesylate in advanced dermatoﬁbrosarcoma protuberans:
pooled analysis of two phase II clinical trials,” Journal of
Clinical Oncology, vol. 28, no. 10, pp. 1772–1779, 2010.
[107] J. D. G. Goldberg, E. Choy, L. Rosen et al., “Preliminary
results from a phase II study of ARQ197 in patients
with microphthalmia transcription family (MiT)-associated
tumors,” Journal of Clinical Oncology, vol. 27, abstract 10502,
2009.
[108] H. V. Erkizan, Y. Kong, M. Merchant et al., “A small molecule
blocking oncogenic protein EWS-FLI1 interaction with RNA
helicase A inhibits growth of Ewing’s sarcoma,” Nature
Medicine, vol. 15, no. 7, pp. 750–756, 2009.
[109] C. J. Breitbach, J. Burke, D. Jonker et al., “Intravenous
delivery of a multi-mechanistic cancer-targeted oncolytic
poxvirus in humans,” Nature, vol. 477, pp. 99–102, 2011.
[110] G. Li, H. Kawashima, A. Ogose et al., “Eﬃcient virotherapy
for osteosarcoma by telomerase-speciﬁc oncolytic aden-
ovirus,”JournalofCancerResearchandClinicalOncology,vol.
137, no. 6, pp. 1037–1051, 2011.
[111] R. T. Kurmasheva, L. Dudkin, C. Billups, L. V. Debelenko,
C. L. Morton, and P. J. Houghton, “The insulin-like growth
factor-1 receptor-targeting antibody, CP-751,871, suppresses
tumor-derived VEGF and synergizes with rapamycin in
models of childhood sarcoma,” Cancer Research, vol. 69, no.
19, pp. 7662–7671, 2009.
[112] F. Huang, A. Greer, W. Hurlburt et al., “The mechanisms
of diﬀerential sensitivity to an insulin-like growth factor-1
receptor inhibitor (BMS-536924) and rationale for combin-
ing with EGFR/HER2 inhibitors,” Cancer Research, vol. 69,
no. 1, pp. 161–170, 2009.
[113] A. S. Martins, J. L. Ordo˜ nez, A. Garc´ ıa-S´ anchez et al., “A
pivotal role for heat shock protein 90 in Ewing sarcoma resis-
tance to anti-insulin-like growth factor 1 receptor treatment:
in vitro and in vivo study,” Cancer Research, vol. 68, no. 15,
pp. 6260–6270, 2008.
[114] R. Quek, Q. Wang, J. A. Morgan et al., “Combination mTOR
and IGF-1R inhibition: phase I trial of everolimus and
ﬁgitumumab in patients with advanced sarcomas and other
solid tumors,” Clinical Cancer Research,v o l .1 7 ,n o .4 ,p p .
871–879, 2011.
[115] A. Naing, R. Kurzrock, A. Burger et al., “Phase I trial of
cixutumumab combined with temsirolimus in patients with
advanced cancer,” ClinicalCancerResearch,vol. 17, pp. 6052–
6060, 2011.
[116] J. E. Butrynski, D. R. D’Adamo, J. L. Hornick et al.,
“Crizotinib in ALK-rearranged inﬂammatory myoﬁbroblas-
tic tumor,” New England Journal of Medicine, vol. 363, no. 18,
pp. 1727–1733, 2010.
[117] A. Zibat, E. Missiaglia, A. Rosenberger et al., “Activation of
the hedgehog pathway confers a poor prognosis in embry-
onal and fusion gene-negative alveolar rhabdomyosarcoma,”
Oncogene, vol. 29, no. 48, pp. 6323–6330, 2010.
[118] M. Hirotsu, T. Setoguchi, H. Sasaki et al., “Smoothened as a
new therapeutic target for human osteosarcoma,” Molecular
Cancer, vol. 9, article 5, 2010.
[119] T. D. Tiet, S. Hopyan, P. Nadesan et al., “Constitutive
Hedgehog signaling in chondrosarcoma up-regulates tumor
cell proliferation,” American Journal of Pathology, vol. 168,
no. 1, pp. 321–330, 2006.
[120] J. Joo, L. Christensen, K. Warner et al., “GLI1 is a central
mediator of EWS/FLI1 signaling in Ewing Tumors,” PLoS
ONE, vol. 4, no. 10, Article ID e7608, 2009.
[121] E. Beauchamp, G. Bulut, O. Abaan et al., “GLI1 is a direct
transcriptional target of EWS-FLI1 oncoprotein,” Journal of
Biological Chemistry, vol. 284, no. 14, pp. 9074–9082, 2009.
[122] J. Roma, A. Masi` a, J. Revent´ os, J. S. De Toledo, and S.
Gallego, “Notch pathway inhibition signiﬁcantly reduces
rhabdomyosarcoma invasiveness and mobility in vitro,”
Clinical Cancer Research, vol. 17, no. 3, pp. 505–513, 2011.
[123] M. Tanaka, T. Setoguchi, M. Hirotsu et al., “Inhibition of
Notch pathway prevents osteosarcoma growth by cell cycle
regulation,” British Journal of Cancer, vol. 100, no. 12, pp.
1957–1965, 2009.
[124] E. R. Sampson, V. Amin, E. M. Schwarz, R. J. O’Keefe, and
R. N. Rosier, “The histone deacetylase inhibitor vorinostat
selectively sensitizes ﬁbrosarcoma cells to chemotherapy,”
Journal of Orthopaedic Research, vol. 29, no. 4, pp. 623–632,
2011.
[125] L. Su, H. Cheng, A. V. Sampaio, T. O. Nielsen, and T.
M. Underhill, “EGR1 reactivation by histone deacetylase
inhibitors promotes synovial sarcoma cell death throughSarcoma 13
the PTEN tumor suppressor,” Oncogene, vol. 29, no. 30, pp.
4352–4361, 2010.
[126] A. Hrzenjak, F. Moinfar, M. L. Kremser et al., “Histone
deacetylase inhibitor vorinostat suppresses the growth of
uterine sarcomas in vitro and in vivo,” Molecular Cancer, vol.
9, article 49, 2010.
[127] T. O. Nielsen, A. Nguyen, L. Su, B. Campbell, and N. M.
Poulin, “Synergism of heat shock protein 90 and histone
deacetylase inhibitors in synovial sarcoma,” Sarcoma, vol.
2009, Article ID 794901, 2009.
[128] J. M. Lubieniecka, D. R. H. De Bruijn, L. Su et al., “Histone
deacetylase inhibitors reverse SS18-SSX-mediated polycomb
silencing of the tumor suppressor early growth response 1 in
synovial sarcoma,” Cancer Research, vol. 68, no. 11, pp. 4303–
4310, 2008.
[129] M. C. Manara, G. Nicoletti, D. Zambelli et al., “NVP-BEZ235
as a new therapeutic option for sarcomas,” Clinical Cancer
Research, vol. 16, no. 2, pp. 530–540, 2010.
[130] C. R. M¨ uller, E. B. Paulsen, P. Noordhuis, F. Pedeutour, G.
S æ t e r ,a n dO .M y k l e b o s t ,“ P o t e n t i a lf o rt r e a t m e n to fl i p o s a r -
comas with the MDM2 antagonist Nutlin-3A,” International
Journal of Cancer, vol. 121, no. 1, pp. 199–205, 2007.
[131] M. S. Brassesco, M. A. Cortez, E. T. Valera et al., “Cryptic
SYT/SXX1 fusion gene in high-grade biphasic synovial
sarcoma with unique complex rearrangement and extensive
BCL2 overexpression,” Cancer Genetics and Cytogenetics, vol.
196, no. 2, pp. 189–193, 2010.
[132] O. M. Tirado, S. Mateo-Lozano, and V. Notario, “Roscovitine
is an eﬀective inducer of apoptosis of Ewing’s sarcoma family
tumor cells in vitro and in vivo,” Cancer Research, vol. 65, no.
20, pp. 9320–9327, 2005.